Edition:
United States

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.58EUR
15 Dec 2017
Change (% chg)

€-0.01 (-0.39%)
Prev Close
€2.59
Open
€2.58
Day's High
€2.62
Day's Low
€2.57
Volume
29,253
Avg. Vol
121,214
52-wk High
€3.79
52-wk Low
€2.40

Select another date:

Wed, Dec 6 2017

BRIEF-Transgene Collaborates with BioInvent To Treat Solid Tumors

* BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS

BRIEF-Transgene successfully raises 14.4 million euros

* TRANSGENE SUCCESSFULLY RAISES € 14.4 MILLION FROM U.S. AND EUROPEAN INVESTORS

BRIEF-Transgene launches capital increase by accelerated book-build offering

* TRANSGENE LAUNCHES A CAPITAL INCREASE BY WAY OF AN ACCELERATED BOOK-BUILD OFFERING

BRIEF-Transgene announces first patient has been treated in TG6002 trial

* ‍FIRST PATIENT TREATED IN A PHASE 1/2A TRIAL (ONCOVIRAC) OF NOVEL ONCOLYTIC VIRUS TG6002 IN RECURRENT GLIOBLASTOMA​

BRIEF-Transgene's TG1050 well tolerated and induces strong specific immune response

* TG1050 IS WELL TOLERATED AND INDUCES A STRONG SPECIFIC IMMUNE RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene Q3 operating revenue drops to 1.4‍​ million euros

* Q3 OPERATING REVENUE EUR 1.4‍​ MILLION VERSUS EUR 1.5 MILLION YEAR AGO

BRIEF-Transgene presents clinical data on TG1050 regarding chronic hepatitis B​

* ‍TRANSGENE PRESENTS FIRST CLINICAL DATA INDICATING THAT TG1050 INDUCES A ROBUST AND HBV-SPECIFIC CELL-MEDIATED IMMUNE RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS B​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene peer reviewed TG4010’s ability to induce broad CD8+ responses

* PEER REVIEWED SCIENTIFIC PUBLICATIONS HIGHLIGHT TG4010’S ABILITY TO INDUCE BROAD CD8+ RESPONSES AND ITS SYNERGISTIC EFFECTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene and Randox sign collaboration to develop oncolytic virotherapies

* TRANSGENE AND RANDOX SIGN COLLABORATION TO DEVELOP INNOVATIVE MULTIFUNCTIONAL ONCOLYTIC VIROTHERAPIES FOR SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene H1 operating loss widens at 16.1 million euros

* TRANSGENE: FIRST HALF-YEAR 2017 IN LINE WITH OUR OBJECTIVES: ALL CLINICAL PROGRAMS PROGRESSING AND NEW COLLABORATION AGREEMENTS SIGNED

Select another date: